Acrivon introduces ACR-525 and PKCθ inhibitor preclinical I&I programs targeting EoE

Acrivon Therapeutics, Inc.

Nov 10, 2026 R&D webcast introduced ACR-525 and a PKCθ inhibitor, both preclinical, with initial development plans in eosinophilic esophagitis (EoE).
Dr. Arjan Bredenoord (Amsterdam UMC), EoE principal investigator, covered epidemiology and unmet need; Dr. Evan Dellon (UNC) reviewed EoE standard of care.
Programs were identified with Acrivon's AI-driven AP3 platform and mark the company's entry into immunology and inflammation.
No preclinical data, IND timing, trial endpoints or financial terms were disclosed; the posted exhibit is only a title slide.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.